{"protocolSection":{"identificationModule":{"nctId":"NCT06554717","orgStudyIdInfo":{"id":"2024P001703"},"organization":{"fullName":"Massachusetts General Hospital","class":"OTHER"},"briefTitle":"Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV","officialTitle":"Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV","acronym":"TRIUMPH"},"statusModule":{"statusVerifiedDate":"2026-05","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-07-10","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2028-06-16","type":"ESTIMATED"},"completionDateStruct":{"date":"2028-12-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-08-12","studyFirstSubmitQcDate":"2024-08-12","studyFirstPostDateStruct":{"date":"2024-08-15","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-05-15","lastUpdatePostDateStruct":{"date":"2026-05-19","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Lindsay Fourman, MD","investigatorTitle":"Assistant Professor of Medicine","investigatorAffiliation":"Massachusetts General Hospital"},"leadSponsor":{"name":"Massachusetts General Hospital","class":"OTHER"},"collaborators":[{"name":"University of Colorado, Denver","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"People with HIV experience earlier impairments in physical function compared to people in the general population. They also exhibit an earlier presentation and more rapid development of frailty, a multisystemic syndrome of aging characterized by reduced activity, fatigue, slowness, weakness, and weight loss. While exercise can improve physical function in people with HIV, it is less effective in doing so than in the general population and is difficult to sustain in the long-term.\n\nThe goal of this clinical trial is to learn whether the medication tesamorelin will improve physical function and muscle health in adults with HIV when combined with exercise. Tesamorelin is a growth hormone-releasing hormone analogue that is FDA-approved to treat abdominal fat accumulation in people with HIV. While tesamorelin has also been shown to increase muscle mass and improve measures of muscle health, its effects on physical performance and muscle strength have not yet been evaluated.\n\nDuring a 24-week intervention phase, half of participants will be randomly assigned to receive tesamorelin and half of participants will be randomly assigned to receive placebo (a look-alike substance that contains no drug). All participants also will engage in a home-based exercise intervention supervised by an exercise coach. During a subsequent 24-week extension phase, individuals will be monitored off study drug and supervised exercise, and be encouraged to continue to exercise independently.\n\nThe investigators will investigate effects of tesamorelin on physical function, muscle mass and quality, quality of life, and exercise adherence and self-efficacy. They also will evaluate whether effects of tesamorelin are maintained following treatment cessation. This study may identify an important strategy to improve how individuals aging with HIV function and feel with potential applications to other patient populations."},"conditionsModule":{"conditions":["HIV-1-infection","Frailty","Impaired Physical Function","Abdominal Obesity","Aging"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":100,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Tesamorelin Plus Exercise","type":"ACTIVE_COMPARATOR","description":"Tesamorelin WR 1.28 mg given subcutaneously daily plus home-based semi-supervised exercise intervention","interventionNames":["Drug: Tesamorelin","Behavioral: Exercise"]},{"label":"Placebo Plus Exercise","type":"PLACEBO_COMPARATOR","description":"Identical placebo given subcutaneously daily plus home-based semi-supervised exercise intervention","interventionNames":["Drug: Placebo","Behavioral: Exercise"]}],"interventions":[{"type":"DRUG","name":"Tesamorelin","description":"Tesamorelin WR 1.28 mg given subcutaneously daily","armGroupLabels":["Tesamorelin Plus Exercise"],"otherNames":["Egrifta, TH9507, growth hormone-releasing hormone analogue"]},{"type":"DRUG","name":"Placebo","description":"Identical placebo injection given subcutaneously daily","armGroupLabels":["Placebo Plus Exercise"]},{"type":"BEHAVIORAL","name":"Exercise","description":"Home-based semi-supervised exercise program","armGroupLabels":["Placebo Plus Exercise","Tesamorelin Plus Exercise"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change in Repeated Chair Stand Time","description":"Time to complete 10 repeated chair stands","timeFrame":"Baseline to Week 24"}],"secondaryOutcomes":[{"measure":"Change in Standard and Modified Short Physical Performance Battery (SPPB)","description":"Objective assessment of physical function that includes measures of balance, gait, and strength","timeFrame":"Baseline to Week 24"},{"measure":"Change in 1-Repetition Maximum Leg Press","description":"Maximal weight that can be lifted by lower extremities once using correct form through full range of motion","timeFrame":"Baseline to Week 24"},{"measure":"Change in 400-Meter Walk Time","description":"Time to walk 400 meters at the fastest pace possible","timeFrame":"Baseline to Week 24"},{"measure":"Change in Appendicular Lean Tissue Mass","description":"Dual-energy x-ray absorptiometry (DXA) lean tissue mass in all four extremities","timeFrame":"Baseline to Week 24"},{"measure":"Change in Cross-Sectional Area of Trunk and Thigh Muscles","description":"Computed tomography (CT) cross-sectional area of trunk and thigh muscles","timeFrame":"Baseline to Week 24"},{"measure":"Change in Frailty Phenotype","description":"Fried Frailty Phenotype score, scored from 0 to 5 with higher indicating worse","timeFrame":"Baseline to Week 24"},{"measure":"Change in Quality of Life","description":"36-Item Short Form Health Survey (SF-36), scored from 0 to 100 with higher indicating better","timeFrame":"Baseline to Week 24"},{"measure":"Change in Exercise Self-Efficacy","description":"Exercise Self-Efficacy Scale, scored from 0 to 100 with higher indicating better","timeFrame":"Baseline to Week 24"},{"measure":"Change in Exercise Adherence","description":"FitBit (step count heart rate time), exercise log (movement type, repetitions, load, rate of perceived exertion)","timeFrame":"Baseline to Week 24"},{"measure":"Change in Tissue Density of Trunk and Thigh Muscles","description":"Computed tomography (CT) attenuation of trunk and thigh muscles","timeFrame":"Baseline to Week 24"},{"measure":"Change in Visceral Adipose Tissue Cross-Sectional Area","description":"Computed tomography (CT) cross-sectional area at L4","timeFrame":"Baseline to Week 24"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Men and women, 50-80 years old\n2. Documented HIV infection on suppressive antiretroviral therapy for at least 1 year with HIV-1 RNA \\<200 copies/mL and CD4+ T cell count \\>200/µL 3\n3. Sedentary lifestyle, defined as self-reported physical activity that breaks a sweat \\<3 days/week with no regular resistance exercise in the past 3 months\n4. ≥1 Fried frailty criterion (weakness, slow gait speed, exhaustion, decreased physical activity, or unintentional weight loss as defined by specific thresholds)\n5. Excess abdominal adiposity as indicated by at least one of the following elevated anthropometric measures assessed at Screen: (1) waist circumference ≥102 cm in non-Asian males (≥90 cm in Asian males) or ≥88 cm in non-Asian females (≥80 cm in Asian females); (2) waist-to-hip ratio ≥0.9 in males or ≥0.85 in females; (3) waist-to-height ratio ≥0.5 in males and females\n6. Normal mammogram within 2 years (females ≤74 years old) or prostate specific antigen \\<4 ng/mL (males ≤70 years old) per U.S. Preventive Services Task Force (USPSTF) age-appropriate cancer screening guidelines\n7. For females, postmenopausal defined as no menses for ≥12 months and anti-müllerian hormone (AMH) \\<20 pg/mL or history of bilateral oophorectomy at least 3 months ago\n8. Provider approval to participate\n\nExclusion Criteria:\n\n1. Use of tesamorelin or other growth hormone (GH)-based therapy within 6 months\n2. Insulin-like growth factor 1 (IGF-1) z-score \\>2.0\n3. HbA1c \\>8%\n4. Active or suspected malignancy (with the exception of non-melanoma skin cancer) within 24 months\n5. Supraphysiologic testosterone or corticosteroid exposure, or change in exogenous testosterone or corticosteroid dose within 3 months\n6. Change in glucose-lowering medication (e.g., glucagon-like peptide-1 receptor agonists) within 3 months\n7. Active or unstable coronary artery disease, chest pain suspicious for angina, or serious arrythmia\n8. History of hypopituitarism, head irradiation, or other conditions known to affect the GH/IGF-1 axis\n9. Known hypersensitivity to tesamorelin or mannitol\n10. Acute or chronic illness judged by the investigator to represent a contraindication to study participation","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Lindsay T. Fourman, MD","role":"CONTACT","phone":"617-643-4590","email":"lfourman@mgb.org"},{"name":"Kristine M. Erlandson, MD","role":"CONTACT","phone":"303-724-4941","email":"kristine.erlandson@cuanschutz.edu"}],"overallOfficials":[{"name":"Lindsay T. Fourman, MD","affiliation":"Massachusetts General Hospital","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Kristine M. Erlandson, MD","affiliation":"University of Colorado, Denver","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"University of Colorado - Anschutz Medical Campus","status":"RECRUITING","city":"Aurora","state":"Colorado","zip":"80045","country":"United States","contacts":[{"name":"Kristine M. Erlandson, MD","role":"CONTACT","phone":"3037244941","email":"kristine.erlandson@cuanschutz.edu"}],"geoPoint":{"lat":39.72943,"lon":-104.83192}},{"facility":"Massachusetts General Hospital","status":"RECRUITING","city":"Boston","state":"Massachusetts","zip":"02114","country":"United States","contacts":[{"name":"Lindsay T Fourman, MD","role":"CONTACT","phone":"6176434590","email":"LFourman@mgb.org"},{"name":"Julia Johnson","role":"CONTACT","phone":"617-724-5545","email":"jjohnson110@mgh.harvard.edu"}],"geoPoint":{"lat":42.35843,"lon":-71.05977}}]},"referencesModule":{"references":[{"pmid":"42419889","type":"DERIVED","citation":"Erlandson KM, Gustafson L, Johnson JE, Kulik GL, Khuu V, Chahal N, Walpert AR, Galdamez ME, Zorgno I, Foldyna B, Jarraya M, Reusch JE, Lee H, Grinspoon SK, Jankowski CM, Fourman LT. Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol. BMJ Open. 2026 Jul 8;16(7):e120740. doi: 10.1136/bmjopen-2026-120740."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-08"},"conditionBrowseModule":{"meshes":[{"id":"D000073496","term":"Frailty"},{"id":"D056128","term":"Obesity, Abdominal"}],"ancestors":[{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"},{"id":"D009765","term":"Obesity"},{"id":"D050177","term":"Overweight"},{"id":"D044343","term":"Overnutrition"},{"id":"D009748","term":"Nutrition Disorders"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D001835","term":"Body Weight"},{"id":"D012816","term":"Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"C479538","term":"tesamorelin"},{"id":"D054439","term":"Ghrelin"},{"id":"D015444","term":"Exercise"}],"ancestors":[{"id":"D036361","term":"Peptide Hormones"},{"id":"D006728","term":"Hormones"},{"id":"D006730","term":"Hormones, Hormone Substitutes, and Hormone Antagonists"},{"id":"D010455","term":"Peptides"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D009043","term":"Motor Activity"},{"id":"D009068","term":"Movement"},{"id":"D009142","term":"Musculoskeletal Physiological Phenomena"},{"id":"D055687","term":"Musculoskeletal and Neural Physiological Phenomena"}]}},"hasResults":false}